ReviewThe Psychiatric clinics of North America2022
Coronavirus Disease 2019 and the Impact on Substance Use Disorder Treatments.
Review in The Psychiatric clinics of North America, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Opioid Overdose-Related Emergency Department Visits Pre- and Post-COVID-19.The western journal of emergency medicine · 2026Article
- The impact of COVID-19 social disruptions on general-, mental- and substance use healthcare services among people with and without HIV in the United States.BMC health services research · 2025Article
- Hospital Provider's Perspectives on MOUD Initiation and Continuation After Inpatient Discharge.Journal of general internal medicine · 2025Article
- Article
- Healthcare utilization trends among patients with opioid use disorder in U.S. Hospitals: an analysis of length of stay, total charges, and costs, 2005-2020.BMC health services research · 2025Article
- Mining Social Media for Barriers to Opioid Recovery with LLMs.Proceedings of the ... Workshop on Patient-Oriented Language Processing · 2025Article
- Trends in Treatment Need and Receipt for Substance Use Disorders in the US.JAMA network open · 2025Article
- Telehealth Disparities in Outpatient Substance Use Disorder (SUD) Treatment among Medicaid Beneficiaries during COVID-19.Substance use & misuse · 2025Article
- Greater impact of COVID-19 on peer-supported addiction services than government-owned services for addiction in Japan: A nationwide 3-year longitudinal cohort study.PCN reports : psychiatry and clinical neurosciences · 2024Article
- Changes in the Success and Characteristics of Tobacco Dependence Treatment before and during the COVID-19 Pandemic: Clinical Sample Comparisons.Medicina (Kaunas, Lithuania) · 2024Article
- Changes in Substance Use Diagnoses in the Great Plains during the COVID-19 Pandemic.Healthcare (Basel, Switzerland) · 2024Article
- Changes in substance use, recovery, and quality of life during the initial phase of the COVID-19 pandemic.PloS one · 2024Article
- Article
- Art therapy's engagement of brain networks for enduring recovery from addiction.Frontiers in psychiatry · 2024Article
- Treatment access gap during the COVID-19 Pandemic: impact on problematic alcohol use and the moderating roles of perceived stress and resilience.Frontiers in psychiatry · 2024Article
- Article
- Impact of the COVID-19 pandemic on burnout and perceived workplace quality among addiction treatment providers.Addiction science & clinical practice · 2023Article
- Trends in deaths following drug use in England before, during, and after the COVID-19 lockdowns.Frontiers in public health · 2023Article
- A randomized, sham-controlled, quintuple-blinded trial to evaluate the NET device as an alternative to medication for promoting opioid abstinence.Contemporary clinical trials communications · 2022Article
- Practical Technology for Expanding and Improving Substance Use Disorder Treatment: Telehealth, Remote Monitoring, and Digital Health Interventions.The Psychiatric clinics of North America · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronavirus disease 2019 (COVID-19)-related stressors and restrictions, in the absence of social and institutional support, have led many individuals to either increase their substance consumption or relapse. Consequently, treatment programs for substance use disorders (SUDs) made a transition from in-person to remote care delivery. This review discusses the following evidence regarding changes prompted by the COVID pandemic to the clinical care of individuals with SUDs: (1) reduction in availability of care, (2) increase in demand for care, (3) transition to telemedicine use, (4) telemedicine for treatment of opioid use disorders, and (5) considerations for use of telemedicine in treating SUDs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.